期刊文献+

2型糖尿病肾病患者血清nesfatin-1的变化及其临床意义

Change of serum level of nesfatin-1 in type 2 diabetic patients with nephropathy
下载PDF
导出
摘要 目的检测2型糖尿病肾病(DN)患者血清nesfatin-1水平,探讨血清nesfatin-1水平与2型糖尿病肾病的关系。方法根据尿清蛋白/肌酐比值(ACR)将115例2型糖尿病患者分为正常清蛋白尿组(NA组,38例)、微量清蛋白尿组(MA组,39例)及临床清蛋白尿组(CP组,38例),选取同期健康体检人群作为对照组(NC组,40例)。采用酶联免疫吸附法(ELISA)测定血清nesfatin-1水平,同时测定患者空腹血糖(FPG)、空腹胰岛素(FINS)、糖化血红蛋白(Hb A1c)、血脂、血肌酐(Scr)、尿素氮(BUN)、C反应蛋白(CRP),计算体重指数(BMI)、胰岛素抵抗指数(HOMA-IR),比较各组间的差异并进行相关分析。结果与NC组比较,3组糖尿病患者血清nesfatin-1水平均显著降低(P<0.05);与NA组、MA组比较,CP组的nesfatin-1最低(P<0.05),而NA组和MA组比较差异无统计学意义(P>0.05);相关分析显示血清nesfatin-1与收缩压、HOMA-IR、Scr、ACR、CRP呈负相关(r=-0.243、-0.486、-0.374、-0.228和-0.219,P<0.05);多元线性回归分析显示HOMAIR、Scr、ACR与血清nesfatin-1独立相关r=0.352、0.264和0.225);控制HOMA-IR影响,偏相关分析结果发现血清nesfatin-1与其他指标均无明显相关性(P>0.05)。结论 T2DM患者nesfatin-1水平降低,而且DN患者CP组nesfatin-1水平最低。DN患者血清nesfatin-1水平的下降可能与胰岛素抵抗的加重密切相关。 [Objective] To investigate the change of serum nesfatin-1 in type 2 diabetic patients with nephropathy. [Methods] A total of 115 patients with type 2 diabetes mellitus were divided into three groups according to the urinary albumin/creatinine ratio (ACR): normal albuminuria group (NA group) with 38 cases, micro-albuminuria group (MA group) with 39 cases and macro-albuminuria group (CP group) with 38 cases; and 40 healthy subjects were included as controls. Serum level of nesfatin-1 was assayed by enzyme linked immunosorbent assay (ELISA). Fasting plasma glucose (FPG), fasting plasma insulin (FINS), HbAlc, lipids, serum ereatinine (Scr), blood urea nitrogen (BUN) and C-reactive protein (CRP) levels together with ACR were also determined. [Results] Serum nesfatin-1 level in the diabetic patients was significantly lower than that in the controls (P〈 0.05); the lowest level was in the CP group which was significantly different from those in the groups NA and MA (P〈 0.05). The levels of nesfatin-1 were negatively correlated with systolic pressure, HOMA-IR, Scr, ACR and CRP (r=-0.243, -0.486, -0.374, -0.228 and -0.219, P〈 0.05). Multiple linear re- gression analysis showed that HOMA-IR, Scr and ACR were independent related factors to the serum nes- fatin-1 (r=0.352, 0.264 and 0.225), Control the effect of HOMA-IR, partial correlation analysis showed that serum nesfatin-1 and other parameters were not significantly correlated (P〉 0.05). [Conclusions] Serum nesfatin-1 level in diabetic patients is significantly lower than that in health controls, and it is the lowest in the patients with macro-albuminuria. The decrease of serum nesfatin-1 level could be associated with increased insulin resistance.
出处 《中国现代医学杂志》 CAS 北大核心 2015年第33期36-39,共4页 China Journal of Modern Medicine
关键词 糖尿病肾病 尿清蛋白/肌酐比值 NESFATIN-1 diabetic nephropathy urinary albumin/creatinine ratio nesfatin-1
  • 相关文献

参考文献13

  • 1中华医学会糖尿病学分会.中国2型糖尿病防治指南[M].北京:北京大学医学出版社,2013:447-498.
  • 2牛春波,李建华.糖尿病肾病发病机制及治疗研究新进展[J].国际检验医学杂志,2014,35(16):2204-2206. 被引量:23
  • 3GONZALEZ R, REINGOLD BK, GAO X, et al. Nesfatin-1 ex- erts a direct, glucose-dependent insulinotropic action on mouse islet β-and MIN6 cells[J]. J Endocrinol, 2011, 208(3): R9-16.
  • 4AYADA C, TORU U, KORKUT Y. Nesfatin-1 and its effects on different systems[J]. Hippokratia, 2015, 19(1): 4-10.
  • 5DING S, QU W, DANG S, et al. Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial dis- ease[J]. Med Sci Monit, 2015, 21(4): 987-991.
  • 6LIU F, YANG Q, GAO N, et al. Decreased plasma nesfatin-1 level is related to the thyroid dysfunction in patients with type 2 diabetes mellitus[J]. J Diabetes Res, 2014, 2014: 128014.
  • 7RIVA M, NITERT MD, VOSS U, et al. Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects[J]. Cell Tissue Res, 2011, 346(3): 393-405.
  • 8ZHANG Z, LI L, YANG M, et al. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mel- litus[J]. Exp Clin Endocrinal Diabetes, 2012, 120(2): 91-95.
  • 9谭丽艳,齐亚灵,李洪源,徐海波.初诊老年肥胖2型糖尿病患者血清nesfatin-1及apelin水平与胰岛素抵抗的关系[J].中国老年学杂志,2014,34(8):2034-2035. 被引量:17
  • 10BLASLOV K, BULUM T, DUVNJAK L. Pathophysiological fac- tors in the development of diabetic nephropathy-new insights[J]. Acta Med Croatica, 2014, 68(2): 135-140.

二级参考文献40

  • 1Packham DK, Alves TP, Dwyer JP, et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabe- tes and nephropathy., results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database [J]. Am J Kidney Dis,2012,59(1),75- 83.
  • 2Mason RM, Wahab NA. Extracellular matrix metabolism in dia- betic nephropathy [J ]. J Am Soc Nephrol, 2003, 14 ( 5 ) : 1358- 1373.
  • 3Elmarakby AA,Sullivan JC. Relationship between oxidative stress and inflammatory eytokines in diabetic nephropathy[J]. Cardio- vasc Ther,2012,30(1) :49-59.
  • 4Giaceo F,Brownlee M. Oxidative stress and diabetic complications[J]. Circ Res, 2010,107 (1) : 1058-1070.
  • 5Murarka S, Movahed MR. Diabetic cardiomyopathy[J]. J Card Fail,2010,16(1):971- 979.
  • 6Dronavalli S,Duka I,Bakris GL. The pathogenesis of diabetic ne- phropathy[J]. J Nat Clin Pract Endocrinol Metab,2008,4(8) 444 -452.
  • 7Lewko B, Latawiec E, Maryn A, et al. Osmolarrity and glucose differentially regulation aldose reduetase activity in cultured mouse podocytes[J]. Exp Diabets Res,2011,20(11) :278963.
  • 8H uang P,Zhang Y,Jiang T, et al, Role of aldose reduetase in the high glucose induced expression of fibronectin in human mesangial cells[J]. J Mol Biol Rep,2010,37(6):3017-3021.
  • 9Sebekova K,Faist V, Hofmann T, et al. Effects of a diet rich in advanced giycation end products in the rat remnant kidney model [J]. Am J Kindney Dis,2003,41(3) :48-51.
  • 10Kanwar YS, Wada J, Sun L, et al. Diabetic nephropathyz mecha nisms of renal disease progressi on[J]. Exp Biol Med, 2008,233 (2) :4-11.

共引文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部